Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial

Matthijs P. Raadsen, Christine Dahlke, Anahita Fathi, Svenja Hardtke, Michael Klüver, Verena Krähling, Gesche K. Gerresheim, Leonie Mayer, Anna Z. Mykytyn, Leonie M. Weskamm, Tamara Zoran, Eric C. M. Van Gorp, Gerd Sutter, Stephan Becker, Bart L. Haagmans, Marylyn M. Addo, Saskia Borregaard, Laura Kaltenberg, Anastasia Kelidou, Thomas Hesterkamp, Klaus Schwamborn, Simon Schröder, Marie-Louise Dieck, Monika Friedrich, Cordula Grüttner, My Linh Ly, Sybille Mellinghoff, Niclas Renevier, Monika Rottstegge, Maren Sandkuhl, Claudia Schlesner, Asisa Volz, Jana Funk, Simone Kardinahl, Andreas Neubert, Georgia Kalomidou, Alina Tscherne, Alexandra Kupke